Although further studies are needed to decipher the precise mechanisms whereby p300-dependent regulation of Myb controls MDS pathogenesis, our study further implicates Myb as a promising target for therapy in MDS or AML patients (42). This evidence concerns the gene MYB and acute myeloid leukemia.